Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 7, 2012, Pages 762-769

  Casellas, Francesc ^a   Barreiro De Acosta, Manuel ^b   Iglesias, Marta ^b   Robles, Virginia ^a   Nos, Pilar ^c   Aguas, Mariam ^c   Riestra, Sabino ^d   De Francisco, Ruth ^d   Papo, Michel ^e   Borruel, Natalia ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d Asturias University Hospital   (Spain)

^e HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Crohn's disease; mucosal healing; quality of life; restoration of health; ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DAILY FATIGUE IMPACT SCALE FATIGUE QUESTIONNAIRE; DEPRESSION; FATIGUE; FEMALE; HEALING; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MUCOSAL HEALING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANXIETY; COLONOSCOPY; DEPRESSION; FATIGUE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMETRICS; QUALITY OF LIFE; REGENERATION; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84862231137     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835414b2     Document Type: Article

References (46)

1. Vergara M, Casellas F, Badia X, Malagelada JR. Assessing the quality of life of household members of patients with inflammatory bowel disease: development and validation of a specific questionnaire. Am J Gastroenterol 2002; 97:1429-1437.
2. Casellas F, Arenas JI, Baudet JS, Fabregas S, Garcia N, Gelabert J, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005; 11: 488-496.
3. Langhorst J, Mueller T, Luedtke R, Franken U, Paul A, Michalsen A, et al. Effects of a comprehensive lifestyle modification program on quality-of-life in patients with ulcerative colitis: a twelve-month follow-up. Scand J Gastroenterol 2007; 42:734-745.
4. Love JR, Irvine EJ, Fedorak AK. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992; 14:15-19.
5. Huamán W, Casellas F, Borruel N, Peláez A, Torrejón A, Castells I, et al. Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life. J Crohns Colitis 2010; 4: 637-641.
6. Rutgeers P, Vermiere S, Van Assche G. Mucosal healing in inflammatory bowel disease: imposible ideal or therapeutic target? Gut 2007; 56: 453-455.
7. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15:1295-1301.
8. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53:1813-1816.
9. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138:463-468.
10. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
11. Rutgeers P, D'Haens G, Van Assche G, Sandborn WJ,Wolf D, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease - first results of the extend trial. Gastroenterology 2009; 136:A116.
12. Barreiro M, Lorenzo A, Mera J, Domínguez-Muñoz JE. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009; 3:271-276.
13. Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15:1302-1307.
14. Lémann M, Jean-Yves M, Colombel JF, Duclos B, Soule JC, Lerebours E, et al. Randomized, double-blind, controlled withdrawal rtial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128:1812-1818.
15. Rutgeerts P, Thakkar R,Wu EQ, Kaltenboeck A, Yang M, Mulani PM, Chao J. Quality-of-life benefits for adalimumab-treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology 2010; 138 (Suppl 1):S320.
16. Casellas F, Alcala MJ, Prieto L, Armengol JR, Malagelada JR. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004; 99:457-461.
17. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102:794-802.
18. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16:338-346.
19. O'Morain C, Tobin A, Leen E, Suzuki Y, O'Riordan T. Criteria of case definition in Crohn's disease and ulcerative colitis. Scand J Gastroenterol Suppl 1989; 170:7-11.
20. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43:29-32.
21. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1:514.
22. Schusselé Filliettaz S, Juillerat P, Burnand B, Arditi C,Windsor A, Beglinger C, et al.; EPAGE II Study Group. Appropriateness of colonoscopy in Europe (EPAGE II) Chronic diarrhea and known inflammatory bowel disease. Endoscopy 2009; 41:218-226.
23. Satsangi J, Silverberg MS, Vermiere S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55:749-753.
24. López Vivancos J, Casellas F, Badía X, Vilaseca J, Malagelada JR. Validation of the Spanish version of the Inflammatory Bowel Disease Questionnaire in ulcerative colitis and Crohn's disease. Digestion 1999; 60:274-280.
25. Bombardier C, Beaton D. Cross-cultural adaptation of health related quality of life instruments: literature review and proposed guidelines. J Clin Epidemiol 1994; 26:1417-1432.
26. Badia W. Transcultural adaptation of health related quality of life measures for its use in Spain. Med Clin 1995; 105:56-58.
27. Konig HH, Ulshofer A, Gregor M, von Tirpitz C, Reinshagen M, Adler G, Leidl R. Validation of the Euroqol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 11:1205-1215.
28. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Invest 1992; 14:15-19.
29. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54:782-7888.
30. Guy W. ECDEU Assessment Manual for Psychopharmacology -Revised (DHEW Publ No ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. 1976. pp. 218-222.
31. Martínez-Martín P, Catalán MJ, Benito-León J, Moreno AO, Zamarbide I, Cubo E, et al. Impact of fatigue in Parkinson's disease: the fatigue impact scale for daily use (D-FIS). Qual Life Res 2006; 15:597-606.
32. Casellas F, López Vivancos J. Fatigue as a determinant of health in patients with celiac disease. J Clin Gastroenterol 2010;423-427.
33. Daperno M, D' Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60:505-512.
34. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105:162-169.
35. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 317:1625-1629.
36. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. Review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132:763-786.
37. Efthymiou A, Viazis N, Mantzaris G, Papadimitriou N, Tzourmakliotis D, Raptis S, Karamanolis DG. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? a prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis 2008; 14:1542-1547.
38. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26:205-215.
39. Flynn A, Kane S. Mucosal healing in Crohn's disease and ulcerative colitis: what does it tell us? Curr Opin Gastroenterol 2011; 27:342-345.
40. Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009; 15:935-950.
41. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57:893-902.
42. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55:47-53.
43. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy. A prospective cohort study. Inflamm Bowel Dis 2010; 16:1905-1911.
44. Badía X, Herdman M, Schiaffino A. Determining correspondence between scores on the EQ-5D "thermometer" and a 5-point categorical rating scale. Med Care 1999; 37:671-6777.
45. Ananthakrishnan AN,Weber LR, Knox JF, Skaros S, Emmons J, Lundeen S, et al. Permanent work disability in Crohn's disease. Am J Gastroenterol 2008; 103:154-161.
46. Vergara M, Montserrat A, Casellas F, Gallardo O, Suarez D, Motos J, et al. Development and validation of the Crohn's disease perceived work disability questionnaire. Inflamm Bowel Dis 2011; 17:2350-2357.